The new age of tailored medicine


Personalised medicine is all about treating an individual based on the specifics of his or her disease. However, both current EMA or FDA regulations and present clinical practice are stochastic, and thereby fundamentally in opposition. If we wish to truly usher in the era of personalised medicine, we need to change this environment. The TREAT1000 project is a good way to begin.

Imagine that you’ve taken your Ferrari to the mechanic because of a breakdown, and the mechanic consults a chart that tells him that a Ferrari with this problem needs a new fuel filter 30% of the time. So he changes your fuel filter. But the problem persists, so he replaces the the next item on the chart – the fuel injectors. This is how he continues until the problem is fixed. Wouldn’t you prefer to go to a mechanic who actually understands how the different parts of your car work together?
Unfortunately, this is still the current “state-of-the-art” in cancer medicine. Your doctor knows what type of cancer you have, and may also know a few additional things about it. Even so, physicians treat cancer patients based primarily on the stage and tissue of origin of their cancer, with no real understanding of what has gone wrong in their tumour cells. For a long time, this has been the only possible treatment, because establishing a cellular blueprint of an individual’s cancer was impossible, both in practical and economic terms.
However, as we approach the 10th anniversary of the UC Santa Cruz publication of the first working draft of the human genome, rapidly dropping sequencing costs will soon make full genome sequencing of all cancer patients a routine diagnostic.Along with the other dividends of the genome project – like the accumulated body of knowledge on the general molecular mechanisms of cancer – this will allow doctors to build a detailed blueprint of the workings an individual’s cancer cells. This very personalised information will allow physicians to identify the right therapy, greatly increasing the chance of successful treatment and reducing side-effects.
Substantial changes in regulatory and medical practice must take place for that to happen, and both the EMA and the FDA are well aware of the challenges. In a recent speech, former FDA Commissioner Andrew von Eschenbach touched on them, saying that “the transformation is not a linear extrapolation of the past. It’s a metamorphosis. The future will look no more like the past than a butterfly looks like a caterpillar.”
A good example for the next step in the development of true individualised medicine for cancer patients is a transatlantic EU-US pilot project called TREAT1000 ( Its goal is to identify the somatic changes in the genomes and transcriptomes of 1,000 cancer patients and to put their diagnoses, therapy recommendations, and clinical data into the public domain. This will allow us to begin a fact-based dialogue with regulatory agencies and medical professionals about the best way to ensure that von Eschenbach’s caterpillar turns into a butterfly.



The first of February marked a milestone for Leverkusen-based Bio­frontera AG in more ways than one. It was the first day that Ameluz, the firm’s first approved product, could be sold in German pharmacies. It was also the date...



Darmstadt – German pharmaceutical and chemical company Merck KGaA has set a downbeat tone for 2012. CEO Karl-Ludwig Kley said the recently launched cost-cutting programme and tough economic conditions will weigh on profits this...



Mainz/Leuna – Two biotech concepts were amongst the winners of the recent third round of the Excellence Cluster initiative, which is funded by the German Ministry for Research. In Mainz the champagne corks popped especially loud...



German Merck KGaA has closed a licencing agreement with US-based Threshold Pharmaceuticals Inc. The cooperation centres around the hypoxia­-activated drug TH-302, which is currently being studied in a global Phase III study....



Munich – Looking back with satisfaction and bent on a prize for good behaviour, German biopharmaceutical company Wilex AG reported yesterday on the fiscal year 2011 and outlined the shores in sight. The 2011 total revenue was...



Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information...


Thousand Oaks/Munich - Bling bling for blinatumomab. It is a compliment for the European life sciences scene and sad news at the same time. Amgen Inc., the world's largest biotechnology company, agreed to buy Micromet Inc., an...



Martinsried - SHELTER is responsible for the fact that the stocks of 4SC behaved like a rodeo horse on Thursday. The shares rose in several stages up to 63%, only to settle at a mere 43% rise at the end of the day. SHELTER is a...



Ludwigshafen – BASF Plant Science GmbH, the agrochemistry and biotech arm of the world-largest chemistry company, thinks that it has outstayed its welcome in Europe. Over the next two years, most of the green biotechnology...



Munich - It is the accolade for Micromet. The German company, which is listed on the U.S. stock exchange, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the renowned US...

Displaying results 1 to 10 out of 454

1-10 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%


  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%


  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%


  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%


  • SANTHERA98.85 CHF2421.7%
  • CYTOS1.01 CHF621.4%
  • WILEX3.59 EUR322.4%


  • MOLOGEN5.07 EUR-55.0%
  • BIOFRONTERA2.41 EUR-26.5%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.04.2015

Current issue

All issues